Centene Expands Further Into Pharmacy With Magellan Deal

January 14

In addition to creating “one of the nation’s largest behavioral health platforms,” Centene Corp. will add another pharmacy-related asset to its portfolio with its recently announced $2.2 billion proposed purchase of Magellan Health, Inc.

The deal, unveiled on Jan. 4, will deliver 2 million PBM members and 16 million medical pharmacy lives to Centene, which already has a variety of internal and external PBM relationships. And while those pharmacy lives are just a slice of the transaction compared with the behavioral health and specialty health assets that Centene will get by purchasing Magellan, they are a key part of the strategic rationale for the deal.

0 Comments

Radar on Drug Benefits

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Prices for COVID-19 Vaccines, Drugs Could Consider Value January 14, 2021

CMS Greenlights Tennessee’s Closed Medicaid Formulary Demo January 14, 2021